Q1 2012 · —
Revenue$102.53M$102.53M +101.5% vs Q1 2011+22.7% vs Q4 2011
Net Income$27.68M$27.68M +26.8% vs Q1 2011−26.1% vs Q4 2011
EPS Diluted$0.48$0.48 ±0.0% vs Q1 2011−39.2% vs Q4 2011
Gross Profit$93,708,000+99.0%
Operating Income$35,739,000+58.1%
Operating Cash Flow$24,295,000−0.6%
Free Cash Flowderived$24,010,000−1.5%
Margins · derived
Gross margin91.4%−1.2 pt vs Q1 2011
Operating margin34.9%−9.6 pt vs Q1 2011
Net margin27.0%−15.9 pt vs Q1 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2012 | Q1 2011 | Q1 2010 |
|---|---|---|---|
| Revenue | $102.53M | $50.88M | $50.88M |
| Net Income | $27.68M | $21.83M | $21.83M |
| EPS Diluted | $0.48 | $0.48 | $0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR